Adaptimmune Therapeutics PLC (ADAP)
1.21
+0.02
(+1.68%)
USD |
NASDAQ |
May 03, 09:51
Adaptimmune Therapeutics Enterprise Value: 146.78M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 02, 2024 | 146.78M |
May 01, 2024 | 151.72M |
April 30, 2024 | 146.78M |
April 29, 2024 | 136.91M |
April 26, 2024 | 118.40M |
April 25, 2024 | 114.70M |
April 24, 2024 | 119.63M |
April 23, 2024 | 134.44M |
April 22, 2024 | 102.36M |
April 19, 2024 | 94.14M |
April 18, 2024 | 74.81M |
April 17, 2024 | 96.68M |
April 16, 2024 | 107.29M |
April 15, 2024 | 112.23M |
April 12, 2024 | 139.38M |
April 11, 2024 | 171.47M |
April 10, 2024 | 166.53M |
April 09, 2024 | 191.21M |
April 08, 2024 | 188.74M |
April 05, 2024 | 191.21M |
April 04, 2024 | 186.28M |
April 03, 2024 | 193.68M |
April 02, 2024 | 198.62M |
April 01, 2024 | 215.89M |
March 28, 2024 | 243.05M |
Date | Value |
---|---|
March 27, 2024 | 243.05M |
March 26, 2024 | 228.24M |
March 25, 2024 | 208.49M |
March 22, 2024 | 208.49M |
March 21, 2024 | 183.81M |
March 20, 2024 | 181.34M |
March 19, 2024 | 201.09M |
March 18, 2024 | 215.89M |
March 15, 2024 | 218.36M |
March 14, 2024 | 213.43M |
March 13, 2024 | 245.51M |
March 12, 2024 | 220.83M |
March 11, 2024 | 233.17M |
March 08, 2024 | 285.01M |
March 07, 2024 | 282.54M |
March 06, 2024 | 275.13M |
March 05, 2024 | 213.43M |
March 04, 2024 | 218.36M |
March 01, 2024 | 214.26M |
February 29, 2024 | 209.72M |
February 28, 2024 | 218.80M |
February 27, 2024 | 241.52M |
February 26, 2024 | 225.62M |
February 23, 2024 | 189.27M |
February 22, 2024 | 166.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-98.43M
Minimum
Mar 15 2022
1.554B
Maximum
Jun 04 2020
243.88M
Average
139.19M
Median
Apr 01 2020
Enterprise Value Benchmarks
Biodexa Pharmaceuticals Plc | -2.147M |
NuCana PLC | -13.56M |
Autolus Therapeutics PLC | 853.39M |
Mereo BioPharma Group PLC | 383.22M |
TC BioPharm (Holdings) PLC | 1.496M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -47.92M |
Revenue (Quarterly) | 0.231M |
Total Expenses (Quarterly) | 50.09M |
EPS Diluted (Quarterly) | -0.18 |
Profit Margin (Quarterly) | -20.74K% |
Earnings Yield | -39.16% |
Normalized Earnings Yield | -46.63 |